Hemp Research — Page 151

Peer-reviewed industrial hemp research papers, sorted by publication date. Browse the latest findings on hemp cultivation, processing, materials science, biomedical applications, and regulatory science from PubMed, OpenAlex, and other indexed sources.

The Use of Cannabinoids in Pediatric Palliative Care—A Retrospective Single-Center Analysis (2024)

This data analysis aimed to systematically analyze a pediatric patient population with a life-limiting disease who were administered cannabinoids. It was a retrospective single-center analysis of patients under supervision of the specialized outpatient pediatric palliative care (SOPPC) team at the Department of Pediatrics and Adolescent Medicine of the Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU). Thirty-one patients with a primary diagnosis of neuropediatric, oncologic, metabolic, an

Uma visão abrangente da epilepsia: etiologia, classificação e manifestações clínicas (2023)

RESUMOA epilepsia é uma doença neurológica crônica que se caracteriza por uma predisposição duradoura a crises epilépticas. Sua etiologia é multifatorial, expressa por uma interação complexa entre fatores genéticos e adquiridos. Fatores hereditários desempenham um papel significativo em certas formas de epilepsia, anormalidades no desenvolvimento cerebral, distúrbios metabólicos e bioquímicos podem contribuir para o desenvolvimento de outras formas. A compreensão dessas diferentes etiologias é f

Probing The Link Between Substance Use and Psychiatric Disorders: Toward A New Paradigm in the Treatment and Prevention of These Intertwined Disorders (2023)

Globally, the rates of substance use and psychiatric disorders continue to escalate, and in the U.S., both disordertypes have become a public health crisis. Concerningly, however, psychological, behavioral, and pharmacological interventions for both disorder-types are failing to keep up with the demands for treatment. Additionally, even with treatment, the long-term prognosis for both disorder-types is equally guarded, with each expected to reduce the lifespan of those affected by an average of

Drug Repurposing in Dermatology: Molecular Biology and Omics Approach (2020)

The withdrawal of several blockbuster drugs due to severe adverse effects and the failure of several developed drugs in clinical trials raised questions about the efficacy of current approaches of drug discovery. Moreover, the limitation of resources and the long and costive process of drug discovery made a lot of pharmaceutical companies to employ drug repurposing strategies to get new insights about activities that were not considered during their initial discovery. The development of therapeu

Cannabis Use for Therapeutic Purposes by Children and Youth at a Tertiary Teaching Hospital in Canada: A Retrospective Chart Review (2020)

ABSTRACTBackground: The study of the use of cannabis for therapeutic purposesin the pediatric population is increasing, yet data on efficacy and safety are limited. Characterization of pediatric cannabis use for therapeuticpurposes will improve understanding of the circumstances under which it occurs and the associated outcomes.Objective: To describe the use of cannabis for therapeutic purposes, regardless of authorization, in a pediatric tertiary teaching hospital.Methods: A retrospective chart

Cannabidiol administration reduces the expression of genes involved in mitochondrial electron transport chain and ribosome biogenesis in mice CA1 neurons (2023)

ABSTRACT Background Cannabidiol (CBD), one of the main cannabinoids present in the female flowers of Cannabis sativa , has been a therapeutic alternative for a plurality of disorders. Previous investigation has already provided insights into the CBD molecular mechanism, however, there is no transcriptome data for CBD effects on hippocampal subfields. Here, we explore the transcriptomic changes in dorsal and ventral CA1 of adult mice hippocampus after 100 mg/kg of CBD administration (i.p.) for on

Understanding the Burden of Lennox−Gastaut Syndrome: Implications for Patients, Caregivers, and Society in High and Low Resource Settings: A Narrative Review (2024)

Managing LGS requires tailored approaches addressing seizures, comorbidities, and caregiver needs. While advancements in treatments and surgical techniques offer hope, challenges persist in achieving optimal outcomes and reducing the societal burden. The management of LGS involves a combination of pharmacological and nonpharmacological therapies, tailored to the individual patient's needs and response to treatment. Regular follow-up with a neurologist specialized in epilepsy is crucial for ongoi

Motivations for Cannabis Use in Individuals with Social Anxiety Disorder (SAD) (2023)

Social anxiety disorder (SAD) is a debilitating psychiatric condition. Consequently, it is common for those affected to resort to cannabis to cope with their symptoms. The primary objective of this study was to understand the differences between motivations for cannabis use in adults with and without SAD. We employed convergent, mixed methods to collect the data. Twenty-six individuals (age: 27.9 ± 7.3 years; 54% female) with and twenty-six (age: 27.4 ± 6.7 years; 50% female) without SAD were ad

Cannabidiol Successful Therapy for Developmental and Epileptic Encephalopathy Related to CYFIP2 (2022)

Background: The knowledge about the molecular basis of epilepsies has increased enormously with the advent of next-generation sequencing (NGS) technology, and CYFIP2 is one of the many genes recently recognized and associated with epilepsy. Pathogenic variants in CYFIP2 cause Developmental and Epileptic Encephalopathy 65 (DEE65), which is characterized by hypotonia, profound developmental delay, and epilepsy. Case Presentation: Herein, we report a 3-year-old male with an early onset epileptic en

Developmentally-regulated impairment of parvalbumin interneuron synaptic transmission in an experimental model of Dravet syndrome (2021)

ABSTRACT Dravet syndrome (DS) is a neurodevelopmental disorder defined by epilepsy, intellectual disability, and sudden death, due to heterozygous variants in SCN1A with loss of function of the sodium channel subunit Nav1.1. Nav1.1-expressing parvalbumin GABAergic interneurons (PV-INs) from pre-weanling Scn1a+/− mice show impaired action potential generation. A novel approach assessing PV-IN function in the same mice at two developmental time points showed that, at post-natal day (P) 16-21, spik

Advances in understanding the role of inflammatory factors and immune cells in the pathology of epilepsy, mediated by neuroimmune interactions within the gut-brain axis (2025)

Epilepsy is a prevalent chronic neurological disorder, affecting approximately 70 million individuals globally, with its pathogenesis primarily attributed to recurrent seizures caused by abnormal neuronal discharges in the brain. Recent research has increasingly recognized the critical role of neuroinflammation in the central nervous system in the onset and progression of epilepsy. Furthermore, the gut-brain axis, a crucial link between gut microbiota and the central nervous system, facilitates

Anesthetic Management of Patient With Dravet Syndrome: A Case Report (2019)

Dravet syndrome (DS) is a rare and severe form of epilepsy that begins in infancy. This is particularly burdensome because repeated epileptic seizures lead to cognitive decline. We describe the case of a 12-year-old girl who was diagnosed with DS and was scheduled to have gingival reduction around her mandibular molars. Despite the patient being intellectually disabled, she was able to cooperate somewhat during medical procedures, including intravenous cannulation. Under the assumption that the

Precision medicine to identify, prevent, and treat pediatric obesity (2024)

Pediatric obesity is a growing health concern that has many secondary adverse health implications. Personalized medicine is a tool that can be used to optimize diagnosis and treatments of many diseases. In this review, we will focus on three areas related to the genetics of pediatric obesity: (i) genetic causes predisposing to pediatric obesity, (ii) pharmacogenomics that may predict weight gain associated with pharmacotherapy, and (iii) pharmacogenomics of anti-obesity pharmacotherapy. This nar